- Report
- May 2025
- 194 Pages
Global
From €3183EUR$3,545USD£2,711GBP
€3537EUR$3,939USD£3,012GBP
- Report
- December 2024
- 120 Pages
Global
From €5342EUR$5,950USD£4,549GBP
- Report
- June 2025
- 89 Pages
Global
From €5252EUR$5,850USD£4,473GBP
- Report
- March 2025
- 182 Pages
Global
From €3434EUR$3,825USD£2,925GBP
€4040EUR$4,500USD£3,441GBP
- Report
- January 2024
- 150 Pages
Global
From €2918EUR$3,250USD£2,485GBP
€4355EUR$4,850USD£3,708GBP
- Report
- July 2024
- 94 Pages
Global
From €3500EUR$4,176USD£3,085GBP
Neglected Tropical Diseases (NTDs) Diagnosis is a subset of the Infectious Disease Testing market. NTDs are a group of diseases that disproportionately affect the world’s poorest populations, and are caused by a variety of pathogens, including bacteria, viruses, and parasites. Diagnosis of NTDs is typically done through a combination of clinical symptoms, laboratory tests, and imaging. Diagnostic tests for NTDs are often limited in availability and accuracy, and are often expensive and difficult to access in resource-limited settings.
In recent years, there has been an increased focus on the development of new diagnostic tests for NTDs, with the aim of improving access to diagnosis and treatment. This has led to the emergence of a number of companies offering NTD diagnostic tests, including Cepheid, BioMérieux, and Qiagen. Other companies, such as Alere, have developed point-of-care tests for NTDs, which can provide rapid diagnosis in resource-limited settings. Show Less Read more